iPSC-RPE in Retinal Degeneration: Recent Advancements and Future Perspectives.
Journal
Cold Spring Harbor perspectives in medicine
ISSN: 2157-1422
Titre abrégé: Cold Spring Harb Perspect Med
Pays: United States
ID NLM: 101571139
Informations de publication
Date de publication:
01 08 2023
01 08 2023
Historique:
pmc-release:
01
08
2025
medline:
3
8
2023
pubmed:
24
1
2023
entrez:
23
1
2023
Statut:
epublish
Résumé
Regenerative medicine is a great hope for patients suffering from diseases for which no effective treatment is available. With the creation of induced pluripotent stem cells (iPSCs) in 2006, research and development has accelerated expeditiously, reaching a practical stage worldwide. The iPSC-regenerative medicine in ophthalmology is one of the pioneers, which has kicked off clinical application ahead of other fields owing to its advantages. The clinical safety issues of iPSC-derived retinal pigment epithelial (iPSC-RPE) transplantation for exudative age-related macular degeneration have been addressed to a certain extent. Preparations are being made for the next clinical study based on the improvement of its therapeutic effects and expansion of indications globally. Steady progress toward the practical applications of regenerative medicine for the treatment of retinal disorders is expected in the future while strengthening global cooperation amid various research areas, clinical fields, and regulations.
Identifiants
pubmed: 36690464
pii: cshperspect.a041308
doi: 10.1101/cshperspect.a041308
pmc: PMC10411862
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 Cold Spring Harbor Laboratory Press; all rights reserved.